Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) Stock Statistics & Valuation Metrics

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has a market cap or net worth of HK$6.48B. The enterprise value is HK$4.84B.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420,285,370 shares outstanding. The number of shares has decreased by -2.65% in one year.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -27.36%.

The current PE Ratio of Guangzhou Innogen Pharmaceutical Group Co Ltd Class H is ―. Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s PEG ratio is -0.36.

In the last 12 months, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H had revenue of 128.11M and earned -332.53M in profits. Earnings per share was -0.76.

In the last 12 months, operating cash flow was -301.64M and capital expenditures -20.09M, giving a free cash flow of -321.73M billion.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H upcoming earnings date is Mar 23, 2026, Before Open (Confirmed).

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H as a current ratio of 2.93, with Debt / Equity ratio of 15.78%

In the past 12 months, Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has paid 0.00 in taxes.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H EV to EBITDA ratio is -34.36, with an EV/FCF ratio of -35.09.

Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has HK$1.21B in cash and marketable securities with HK$166.33M in debt, giving a net cash position of HK$1.04B billion.

Gross margin is 89.03%, with operating margin of -260.64%, and net profit margin of -259.57%.

The average price target for Guangzhou Innogen Pharmaceutical Group Co Ltd Class H is HK$28.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy